Latest CMPI reports update at 2023-12-23: 2022-Q12021-Q42021-Q1
Checkmate Pharmaceuticals logo
Checkmate Pharmaceuticals CMPI
$ 10.5 0.0%

Checkmate Pharmaceuticals Financial Statements 2011-2024 | CMPI

Annual Financial Statements Checkmate Pharmaceuticals

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

52.7 M 213 M - - - - - - - - -

Shares

21.6 M 13.6 M - - - - - - - - -

Historical Prices

2.44 15.7 - - - - - - - - -

Net Income

-61.4 M -36.9 M -28.3 M -20.8 M - - - - - - -

Revenue

- - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - -

Gross Profit

- - - - - - - - - - -

Operating Income

-61.5 M -36.9 M -28.9 M - - - - - - - -

Interest Expense

- - - - - - - - - - -

EBITDA

-61.4 M -36.9 M -28.9 M -21 M - - - - - - -

Operating Expenses

61.5 M 36.9 M 28.9 M 21 M - - - - - - -

General and Administrative Expenses

15.7 M 10.2 M 4.64 M 2.82 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement Checkmate Pharmaceuticals

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - 21.6 M 21.6 M 21.6 M 21.6 M 21.6 M 21.6 M 13.6 M 1.49 M 1.49 M 1.49 M 1.49 M 1.43 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - -15.9 M - -15 M -19 M -14.1 M - -9.83 M -8.35 M -7.8 M - -6.24 M -6.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - -15.9 M - -15 M -19 M -14.2 M - -9.83 M -8.27 M -7.82 M - -6.28 M -6.96 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - -15.8 M - -15 M -19 M -14.2 M - -9.83 M -8.27 M -7.82 M - -6.28 M -6.96 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - 15.9 M - 15 M 19 M 14.2 M - 9.83 M 8.27 M 7.82 M - 6.28 M 6.96 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - 4.24 M - 3.6 M 4.09 M 3.8 M - 3.16 M 1.8 M 1.51 M - 1.21 M 1.11 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency